A Safety and Efficacy Study Evaluating CTX001 in Participants With Transfusion-Dependent β-Thalassemia

NCT03655678 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

COMPLETED

Status

59

Enrollment

INDUSTRY

Sponsor class

Conditions

Beta-Thalassemia
Thalassemia
Genetic Diseases, Inborn
Hematologic Diseases
Hemoglobinopathies

Interventions

BIOLOGICAL: CTX001

Sponsor

Vertex Pharmaceuticals Incorporated

Collaborators

[object Object]